1. Home
  2. TWIN vs LCTX Comparison

TWIN vs LCTX Comparison

Compare TWIN & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twin Disc Incorporated

TWIN

Twin Disc Incorporated

HOLD

Current Price

$17.02

Market Cap

224.5M

Sector

Industrials

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.65

Market Cap

407.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWIN
LCTX
Founded
1918
1990
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
224.5M
407.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TWIN
LCTX
Price
$17.02
$1.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$12.00
$4.25
AVG Volume (30 Days)
27.7K
1.3M
Earning Date
02-04-2026
11-06-2025
Dividend Yield
0.93%
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$347,837,000.00
$10,816,000.00
Revenue This Year
$10.79
$6.32
Revenue Next Year
$8.43
$124.49
P/E Ratio
$924.96
N/A
Revenue Growth
14.24
24.05
52 Week Low
$6.16
$0.37
52 Week High
$17.30
$2.09

Technical Indicators

Market Signals
Indicator
TWIN
LCTX
Relative Strength Index (RSI) 60.25 43.84
Support Level $15.06 $1.63
Resistance Level $18.00 $1.77
Average True Range (ATR) 0.62 0.08
MACD 0.18 -0.01
Stochastic Oscillator 67.18 16.67

Price Performance

Historical Comparison
TWIN
LCTX

About TWIN Twin Disc Incorporated

Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: